Our thoughts are with the friends and family of Steve as well as all those who have lost a loved one on our latest list ...

US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...

My words, thoughts, and ideas are now submerged deep in a vat of midnight dark molasses and some days I can no longer ...

January 07, 2026-- NeuraLight, the leader in developing precision biomarkers for neurology, today announced the completion of PALOMA, a pioneering study comparing eye-movement measures with standard ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

PALOMA study is one of the largest longitudinal studies using eye-movement biomarkers in patients with Parkinson’s diseaseNEW YORK & TEL AVIV, Israel--(BUSINESS WIRE)--NeuraLight, the leader in ...

SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ...

SynuSight Biotech has licensed 18 F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment . SHANGH ...

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...

Cytora Therapeutics Ltd. (Cytora), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell ...

Cell and gene therapies use the body's building blocks - cells and genetic material - to boost the immune system or correct ...

Former radio DJ Kim Johnston is suffering from symptoms like severe speech impairment, jaw instability and is dependent on a ...